|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Isao_Teshirogi
|
|
gptkbp:collaboratedWith
|
gptkb:AstraZeneca
gptkb:Roche
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focus
|
infectious diseases
oncology
pain management
cardiovascular diseases
|
|
gptkbp:founded
|
1878
|
|
gptkbp:founder
|
gptkb:Shobei_Shionogi
|
|
gptkbp:headquarters_location
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shionogi & Co.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:logo
|
Shionogi_logo.svg
|
|
gptkbp:netIncome
|
~¥100 billion
|
|
gptkbp:notableEvent
|
developed COVID-19 antiviral pill (Ensitrelvir)
|
|
gptkbp:notableProduct
|
gptkb:Crestor
gptkb:Xofluza
Oseltamivir (Tamiflu)
|
|
gptkbp:numberOfEmployees
|
5,000+
|
|
gptkbp:officialWebsite
|
https://www.shionogi.com
|
|
gptkbp:parentCompany
|
none (independent)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4507
|
|
gptkbp:subsidiary
|
Shionogi Inc. (US)
|
|
gptkbp:bfsParent
|
gptkb:STH-28
gptkb:Doshomachi,_Chuo-ku,_Osaka,_Japan
gptkb:Fetroja
gptkb:Shobei_Shionogi
gptkb:Baloxavir_marboxil
gptkb:SU_502_110
|
|
gptkbp:bfsLayer
|
7
|